{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T21:56:23Z","timestamp":1768254983441,"version":"3.49.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Among adults who develop coronavirus disease 2019 (COVID-19), those with rheumatic diseases (RDs) have similar hospitalization rates compared with those without RDs. Similar comparisons are lacking in children, due to the overall rarity of COVID-19-related hospitalization in this population. We aimed to examine the risk factors for COVID-19-related hospitalization in paediatric patients with RDs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a systemic literature search in MEDLINE, EMBASE, Web of Science and China National Knowledge Infrastructure from 1 December 2019, through 22 January 2024. We included observational studies based on inclusion and exclusion criteria. Odds ratios (ORs) with 95% CI were calculated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eight cohort studies capturing 1501 paediatric RD patients with SARS-CoV-2 and 118 COVID-19-related hospitalization were included. Odds of hospitalization was increased in children with RDs compared with healthy children. While the diagnosis of juvenile idiopathic arthritis (JIA) was associated with reduced odds of hospitalization overall (OR 0.43 [95% CI: 0.27, 0.68]), systemic JIA was associated with increased odds of hospitalization (OR 2.54 [95% CI: 1.01, 6.40]). The use of glucocorticoids (OR 5.36 [95% CI: 2.21, 13.04]), rituximab (OR 4.62 [95% CI: 1.87, 11.40]), mycophenolate mofetil (OR 4.17 [95% CI: 1.08, 16.16]), hydroxychloroquine (OR 2.97 [95% CI: 1.42, 6.21]), and IL-1 inhibitors (OR 2.28 [95% CI: 1.09, 4.78]) was associated with increased odds of hospitalization, while the use of TNF\u03b1 inhibitors was associated with reduced odds (OR 0.35 [95% CI: 0.20, 0.66]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Children with RDs are at risk of severe COVID-19 outcomes, while children with JIA taking TNF\u03b1 inhibitors might be at a lower risk.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae664","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T22:33:25Z","timestamp":1733870005000},"page":"2369-2376","source":"Crossref","is-referenced-by-count":3,"title":["Risk factors of COVID-19 related hospitalization of paediatric patients with rheumatic diseases: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2145-4602","authenticated-orcid":false,"given":"Qianzi","family":"Zhao","sequence":"first","affiliation":[{"name":"Internal Medicine, Trinity Health Ann Arbor , Ann Arbor, MI,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1802-1427","authenticated-orcid":false,"given":"Beth","family":"Wallace","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Michigan Medicine, VA Ann Arbor Healthcare System , Ann Arbor, MI,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tova","family":"Ronis","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Children\u2019s National Hospital , Washington, DC,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, George Washington University , Washington, DC,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"2025050316131835400_keae664-B1","author":"Risk for COVID-19 Infection, Hospitalization, and Death By Age Group"},{"key":"2025050316131835400_keae664-B2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-0702","article-title":"Epidemiology of COVID-19 among children in China","volume":"145","author":"Dong","year":"2020","journal-title":"Pediatrics"},{"key":"2025050316131835400_keae664-B3","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S1473-3099(20)30287-5","article-title":"Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study","volume":"20","author":"Bi","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2025050316131835400_keae664-B4","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.15585\/mmwr.mm6932e3","article-title":"Hospitalization rates and characteristics of children aged &lt;18 years hospitalized with laboratory-confirmed COVID-19 - COVID-NET, 14 states","volume":"69","author":"Kim","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025050316131835400_keae664-B5","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1542\/hpeds.2021-006084","article-title":"Adjudicating reasons for hospitalization reveals that severe illness from COVID-19 in children is rare","volume":"11","author":"Beck","year":"2021","journal-title":"Hosp Pediatr"},{"key":"2025050316131835400_keae664-B6","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1542\/hpeds.2021-006001","article-title":"\u201cFor COVID\u201d or \u201cWith COVID\u201d: classification of SARS-CoV-2 hospitalizations in children","volume":"11","author":"Kushner","year":"2021","journal-title":"Hosp Pediatr"},{"key":"2025050316131835400_keae664-B7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10096-020-04038-9","article-title":"Children were less frequently infected with SARS-CoV-2 than adults during 2020 COVID-19 pandemic in Warsaw, Poland","volume":"40","author":"Kuchar","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025050316131835400_keae664-B8","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1093\/cid\/ciac388","article-title":"Comparison of influenza and coronavirus disease 2019-associated hospitalizations among children younger than 18 years old in the United States: fluSurv-NET (October-April 2017-2021) and COVID-NET (October 2020-September 2021)","volume":"76","author":"Delahoy","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025050316131835400_keae664-B9","author":"CDC"},{"key":"2025050316131835400_keae664-B10","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.42030","article-title":"SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis","volume":"74","author":"Conway","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025050316131835400_keae664-B11","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s10067-022-06087-1","article-title":"Prevalence and risk of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis","volume":"41","author":"Wang","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2025050316131835400_keae664-B12","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2022-222241","article-title":"Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases","volume":"81","author":"Kearsley-Fleet","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025050316131835400_keae664-B13","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.3390\/jcm11082102","article-title":"Comparisons of clinical features and outcomes of COVID-19 between patients with pediatric onset inflammatory rheumatic diseases and healthy children","volume":"11","author":"Haslak","year":"2022","journal-title":"J Clin Med"},{"key":"2025050316131835400_keae664-B14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12969-021-00568-4","article-title":"Outcomes of COVID-19 in a cohort of pediatric patients with rheumatic diseases","volume":"19","author":"Villacis-Nunez","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025050316131835400_keae664-B15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12969-021-00648-5","article-title":"Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases","volume":"19","author":"Clemente","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025050316131835400_keae664-B16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00296-021-05008-w","article-title":"The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study","volume":"42","author":"Sozeri","year":"2022","journal-title":"Rheumatol Int"},{"key":"2025050316131835400_keae664-B17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","article-title":"MOOSE reporting guidelines for meta-analyses of observational studies","volume":"156","author":"Brooke","year":"2021","journal-title":"JAMA Surg"},{"key":"2025050316131835400_keae664-B18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa scale: comparing reviewers\u2019 to authors\u2019 assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2025050316131835400_keae664-B19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/art.33402","article-title":"Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection","volume":"64","author":"Fiorentino","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025050316131835400_keae664-B20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"2025050316131835400_keae664-B21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2025050316131835400_keae664-B22","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025050316131835400_keae664-B23","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s44197-023-00142-z","article-title":"COVID-19 and pediatric rheumatology: a comprehensive study from a leading tertiary center in Saudi Arabia","volume":"13","author":"Alqanatish","year":"2023","journal-title":"J Epidemiol Glob Health"},{"key":"2025050316131835400_keae664-B24","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00431-021-04276-9","article-title":"Factors associated with hospital and intensive care admission in paediatric SARS-CoV-2 infection: a prospective nationwide observational cohort study","volume":"181","author":"Uka","year":"2022","journal-title":"Eur J Pediatr"},{"key":"2025050316131835400_keae664-B25","doi-asserted-by":"crossref","first-page":"649358","DOI":"10.3389\/fped.2021.649358","article-title":"Epidemiology, clinical features and prognostic factors of pediatric sars-cov-2 infection: results from an italian multicenter study","volume":"9","author":"Garazzino","year":"2021","journal-title":"Front Pediatr"},{"key":"2025050316131835400_keae664-B26","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.semarthrit.2020.06.004","article-title":"Clinical characteristics and risk factors of infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis of observational studies","volume":"50","author":"Yuan","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025050316131835400_keae664-B27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.antiviral.2007.10.011","article-title":"Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK","volume":"77","author":"Kono","year":"2008","journal-title":"Antiviral Res"},{"key":"2025050316131835400_keae664-B28","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025050316131835400_keae664-B29","doi-asserted-by":"crossref","first-page":"105960","DOI":"10.1016\/j.ijantimicag.2020.105960","article-title":"Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection","volume":"55","author":"Fantini","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2025050316131835400_keae664-B30","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of hydroxychloroquine in hospitalized patients with covid-19","volume":"383","author":"Horby","year":"2020","journal-title":"N Engl J Med"},{"key":"2025050316131835400_keae664-B31","first-page":"100243","article-title":"Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE\u2014Coalition V): a double-blind, multicentre, randomised, controlled trial","volume":"11","author":"Avezum","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"2025050316131835400_keae664-B32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40801-022-00300-y","article-title":"Serious cardiovascular adverse events associated with hydroxychloroquine\/chloroquine alone or with azithromycin in patients with covid-19: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Zhao","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"2025050316131835400_keae664-B33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001389","article-title":"Hydroxychloroquine and the risk of respiratory infections among RA patients","volume":"6","author":"Kremer","year":"2020","journal-title":"RMD Open"},{"key":"2025050316131835400_keae664-B34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/mr\/roac148","article-title":"Severe COVID-19 in patients with immune-mediated rheumatic diseases: a stratified analysis from the SORCOM multicentre registry","volume":"34","author":"Boteanu","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2025050316131835400_keae664-B35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025050316131835400_keae664-B36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/apt.16717","article-title":"Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments","volume":"55","author":"Kokkotis","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2025050316131835400_keae664-B37","doi-asserted-by":"crossref","first-page":"1332716","DOI":"10.3389\/fmed.2024.1332716","article-title":"The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population-a comparison of two German registries","volume":"11","author":"Hasseli","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2025050316131835400_keae664-B38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/annrheumdis-2020-218946","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"80","author":"Akiyama","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025050316131835400_keae664-B39","doi-asserted-by":"crossref","first-page":"e2129639","DOI":"10.1001\/jamanetworkopen.2021.29639","article-title":"Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19","volume":"4","author":"Izadi","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025050316131835400_keae664-B40","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"key":"2025050316131835400_keae664-B41","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00296-021-04812-8","article-title":"COVID-19 outcomes in patients with familial Mediterranean fever: a retrospective cohort study","volume":"41","author":"G\u00fcven","year":"2021","journal-title":"Rheumatol Int"},{"key":"2025050316131835400_keae664-B42","doi-asserted-by":"crossref","first-page":"e490","DOI":"10.1016\/S2665-9913(22)00098-4","article-title":"Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform","volume":"4","author":"MacKenna","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2025050316131835400_keae664-B43","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae128","article-title":"Characteristics and risk factors of COVID-19 breakthrough infections in Idiopathic Inflammatory Myopathies: results from the COVAD study","author":"Hoff","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316131835400_keae664-B44","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","article-title":"Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry","volume":"80","author":"Sparks","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae664\/60972194\/keae664.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2369\/60972194\/keae664.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2369\/60972194\/keae664.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:13:38Z","timestamp":1746303218000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/5\/2369\/7918348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae664","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,12,6]]}}}